Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations

被引:96
作者
Chazaud, B
Ricoux, R
Christov, C
Plonquet, A
Gherardi, RK
Barlovatz-Meimon, G
机构
[1] Univ Paris 12, INSERM, U492, Fac Med, F-94000 Creteil, France
[2] Univ Paris 12, INSERM EMI 0011, GERMEN, F-94000 Creteil, France
关键词
D O I
10.1016/S0002-9440(10)64367-2
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The urokinase-type plasminogen activator (uPA) system is a dynamic complex in which the membrane receptor uPAR binds uPA that binds the plasminogen activator inhibitor (PAI)-1 localized in the extracellular matrix, resulting In endocytosis of the whole complex by the low-density lipoprotein receptor-related protein (LRP). High expression of PAI-1 is paradoxically associated with marked tumor spreading and poor prognosis. We previously reported a nonproteolytic role of the [uPAR:uPA:PAI-LRP] complex operative in cell migration. Here we explored whether matrix PAI-1 could be used as a migration support by human breast cancer cells. We showed that the uPA system and LRP are localized at filopodia. of invasive cells, and that formation/internalization of the [uPAR: uPA-PAI-1:LRP] complex is required for attachment and migration of cancer cells; on plastic and on a PAI-1 coat. PAI-1 Increased both filopodia formation and migration of cancer cells suggesting a chemokine-like activity. Migration velocity, expression of the uPA system, use of the [uPAR:uPA:PAI-1:LRP] complex to migrate, and promigratory effects of PAI-1 paralleled cancer cell invasiveness. Phenotyping and functional analysis of invasive cancer cell subclones indicated that different cell subpopulations may use different strategies to migrate depending on both the environment and their expression of the uPA system, some of them taking advantage of abundant available PAI-1.
引用
收藏
页码:237 / 246
页数:10
相关论文
共 59 条
  • [21] SUBSTRATES FOR ASTROCYTOMA INVASION
    GIESE, A
    LOO, MA
    RIEF, MD
    TRAN, N
    BERENS, ME
    [J]. NEUROSURGERY, 1995, 37 (02) : 294 - 301
  • [22] IN-VITRO REGULATION OF HUMAN BREAST-CANCER CELL-ADHESION AND INVASION VIA INTEGRIN RECEPTORS TO THE EXTRACELLULAR-MATRIX
    GUI, GPH
    PUDDEFOOT, JR
    VINSON, GP
    WELLS, CA
    CARPENTER, R
    [J]. BRITISH JOURNAL OF SURGERY, 1995, 82 (09) : 1192 - 1196
  • [23] THE UROKINASE RECEPTOR IS REQUIRED FOR HUMAN MONOCYTE CHEMOTAXIS IN-VITRO
    GYETKO, MR
    TODD, RF
    WILKINSON, CC
    SITRIN, RG
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (04) : 1380 - 1387
  • [24] VERY-LOW-DENSITY LIPOPROTEIN RECEPTOR BINDS AND MEDIATES ENDOCYTOSIS OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR-TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR COMPLEX
    HEEGAARD, CW
    SIMONSEN, ACW
    OKA, K
    KJOLLER, L
    CHRISTENSEN, A
    MADSEN, B
    ELLGAARD, L
    CHAN, L
    ANDREASEN, PA
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (35) : 20855 - 20861
  • [25] HolstHansen C, 1996, CLIN EXP METASTAS, V14, P297
  • [26] Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38α mitogen-activated protein kinase activity
    Huang, S
    New, L
    Pan, ZX
    Han, JH
    Nemerow, GR
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (16) : 12266 - 12272
  • [27] Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation
    Kjoller, L
    Kanse, SM
    Kirkegaard, T
    Rodenburg, KW
    Ronne, E
    Goodman, SL
    Preissner, KT
    Ossowski, L
    Andreasen, PA
    [J]. EXPERIMENTAL CELL RESEARCH, 1997, 232 (02) : 420 - 429
  • [28] Cell migration: A physically integrated molecular process
    Lauffenburger, DA
    Horwitz, AF
    [J]. CELL, 1996, 84 (03) : 359 - 369
  • [29] Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin - Implications for the regulation of pericellular proteolysis
    Lawrence, DA
    Palaniappan, S
    Stefansson, S
    Olson, ST
    FrancisChmura, AM
    Shore, JD
    Ginsburg, D
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (12) : 7676 - 7680
  • [30] Li YH, 1999, ANTICANCER RES, V19, P1223